Company intelligence / Profile preview

BPD Partners

Prague, Czech Republic

Ownership: Private
Development stage: Other

Overview

BPD Partners manages a diversified portfolio of life science companies at various development stages. Notable example: Taveren Therapeutics, a spin-off from IOCB Prague supported by BPD Partners with approximately €4 million in total investment, is approaching final stages of preclinical evaluation for therapeutic compounds targeting LACTB tumor suppressor.[4]

Therapeutic areas: ImmunologyCardiovascularInfectious DiseasesGastroenterologyOncology
Modalities: Small moleculeMonoclonal antibodyGene therapySynthetic biologyCell therapyMicrobiome-based therapyDiagnostic device
Industry: Investors

Partnerships

B3 Holding (owned by Brůžek family) - co-investment partner in BTCZ VenturesIOCB Prague (Institute of Organic Chemistry and Biochemistry)US investors in discussions for Taveren Therapeutics clinical trials

Beyond the preview

Go deeper on BPD Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPD Partners.

Explore the full profile